New UT research collaboration offers promising therapy for prostate, triple negative breast cancer

A research collaboration between the University of Tennessee (UT) Health Science Center, the UT Research Foundation and biopharmaceutical company Veru Inc. has resulted in a promising next generation oral cancer therapy, VERU-111, which has the potential to treat not only advanced prostate cancer, but other cancer types including triple negative breast cancer (TNBC).

The American Association for Cancer Research published an article presenting VERU-111’s positive preclinical results against TNBC in the October edition of Molecular Cancer Therapeutics, a leading journal for the discovery and preclinical development of novel cancer treatments. To learn more, read the recent UT news release (UTRF VERU-111 News Release).

Stay connected with us on Twitter and LinkedIn. Article ideas and other suggestions should be sent to tballard@pyapc.com. Include the name and contact information (phone and email) for follow-up.